sodium zirconium cyclosilicate (Lokelma®) not recommended for use within NHSScotland

The SMC does not recommend sodium zirconium cyclosilicate for treatment of hyperkalaemia in adult patients. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

SPS commentary:

Separately, NICE recommends sodium zirconium cyclosilicate as an option for treating hyperkalaemia in adults only if used in emergency care for acute life-threatening hyperkalaemia alongside standard care or in outpatient care for people with persistent hyperkalaemia and CKD stage 3b to 5 or heart failure (if they have a confirmed serum potassium level of >6.0mmol/litre, are not taking an optimised dosage of RAAS inhibitor because of hyperkalaemia and are not on dialysis).


Scottish Medicines Consortium

Resource links:

NICE TA599 (September 2019)